Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
Conditions
Brief summary
This is a phase Ib/II , open-label, multicenter single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 combined with Carboplatin and Pemetrexed/ Paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Interventions
DRUGAK104 plus Carboplatin and Pemetrexed
Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
DRUGAK104 plus Carboplatin and paclitaxel
Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
Sponsors
Akeso
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent form voluntarily. * Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the informed consent form. * Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. * Expected life expectance ≥ 3 months. * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC. * No prior systemic chemotherapy for advanced or metastatic NSCLC. Subjects who have received prior adjuvant chemotherapy or neoadjuvant chemotherapy with curative intent, or definitive chemoradiotherapy for advanced disease, will be eligible provided that progression has occurred \>6 months from last treatment. * At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously irradiated will not be considered a target lesion. * Subjects must provide an available tumor tissue sample taken \< 1 year prior to first dose of study treatment. * Subjects must provide wild-type epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) reported by tissue-based tests（for non-squamous NSCLC subjects only）. * Adequate organ function. * Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception. * nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective method of contraception from Day 1 and for 120 days after the last dose of investigational product. Key
Exclusion criteria
* Subjects who are diagnosed as NSCLC that harbors an epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation. * Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible * Received prior treatment with EGFR inhibitors or ALK inhibitors. * Is currently participating intervention study or has participated in a study of an investigational agent or investigational device within 4 weeks prior to administration of AK104. * Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as Inducible T-cell co-stimulator (ICOS) or agonists (e.g. CD40, CD137, GITR and OX40 etc). * Subjects who received non-thoracic radiotherapy \>30 Gy within 4 weeks prior to the first dose , or thoracic radiotherapy \>30 Gy within 24 weeks prior to the first dose study drug. * Other active malignancies within 2 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ. * Subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease, * Subjects who require systemic corticosteroids (a dose equivalent to \>10 mg/day prednisone) or other immunosuppressive drugs within 14 days prior to administration of AK104. * Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Active or previously documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis or chronic diarrhea). * Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management. * Known history of active tuberculosis (TB). * An active infection requiring systemic therapy. * Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 1000 IU/ mL or active hepatitis C virus (HCV) should be excluded. Subjects with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA \<1000 IU/ mL) , and cured hepatitis C can be enrolled. Subjects with positive HCV antibodies are eligible only if the HCV RNA test results are negative. * Known history of testing positive for human immunodeficiency virus (HIV). * Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease or active brain metastasis. * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. * Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of subjects experiencing adverse events (AEs) (Phase Ib) | From the time of informed consent through 90 days following termination of treatment with investigational product |
| Objective response rate (ORR) assessed by investigator | Up to 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | Up to 2 years |
| Overall survival (OS) | Up to 2 years |
| Disease control rate (DCR) | Up to 2 years |
| Minimum observed concentration (Cmin) of AK104 at steady state | From first dose of AK104 through 90 days after last dose of AK104 |
| Number of subjects who develop detectable anti-drug antibodies (ADAs) | From first dose of AK104 through 90 days after last dose of AK104 |
| Time to response (TTR) | Up to 2 years |
| Duration of response (DoR) | Up to 2 years |
Countries
China
Outcome results
None listed